A need for greater reporting of socioeconomic status and race in clinical trials

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1700-1701

  Lee, S J ^a   Kavanaugh, A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; ETHNOLOGY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; REVIEW; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; TREATMENT OUTCOME; VALIDATION PROCESS;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; EDUCATIONAL STATUS; HUMANS; RESEARCH DESIGN; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 9644266795     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.019588     Document Type: Review

References (35)

1. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
2. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1470-9.
3. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Longterm safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
4. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
5. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002;137:726-33.
6. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
7. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
8. Mottonen T, Honnonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73.
9. Kirwan J. Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
10. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1994;37:1492-8.
11. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
12. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66.
13. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
14. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
15. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
16. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
17. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: ARMADA trial. Arthritis Rheum 2003;48:35-45.
18. Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chron Dis 1985;38:973-84.
19. Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. Arthritis Rheum 1988;31:1346-57.
20. Criswell LA, Katz PP. Relationship of education level to treatment received for rheumatoid arthritis. J Rheumatol 1994;21:2026-33.
21. Jordan JM. Effect of race and ethnicity an outcomes in arthritis and rheumatic conditions. Curr Opin Rheumatol 1999;11:98-103.
22. Halevy D, Radhakrishnan J, Appel GB. Racial and socioeconomic factors in glomerular disease. Semin Nephrol 2001;21:403-10.
23. Vaccarino V, Gahbauer E, Kasl SV, Charpentier PA, Acampora D, Krumholz HM. Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. Am Heart J 2002;143:1058-67.
24. Al-Othman MO, Morris CG, Logan HL, Hinerman RW, Amdur RJ, Mendenhall WM. Impact of race on outcome after definitive radiotherapy for squamous cell carcinoma of the head and neck. Cancer 2003;98:2467-72.
25. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. Cancer 2003;97:493-8.
26. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-55.
27. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, et al. Age-race subgroup compared with rennin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 1998;280:1168-72.
28. Venter CP, Joubert PH. Ethnic differences in response to β-adrenoceptor blockade by propanolol. J Cardiovasc Pharmacol 1984;6:361-4.
29. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men-a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21.
30. Shavers VL, Lynch CF, Burmeister LF. Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 2002;12:248-56.
31. Robertson, NL. Clinical trial participation. Cancer 1994;74:2687-91.
32. Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans' willingness to participate in medical research studies. Cancer 2001;91(suppl 1):233-6.
33. Fouad MN, Partridge E, Wynn T, Green BL, Kohler C, Nagy S. Statewide Tuskegee Alliance for clinical trials. A community coalition to enhance minority participation in medical research. Cancer 2001;91(suppl 1):237-41.
34. Corbie-Smith G, Thomas S, St George D. Distrust, race, and research. Intern Med 2002;162:2458-63.
35. Gifford AL, Cunningham, WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, et al. Participation in research and access to experiemntal treatments by HIV-infected patients. N Engl J Med 2002;346:1373-82.